TY - JOUR
T1 - Stem cell-derived gametes
T2 - what to expect when expecting their clinical introduction
AU - de Bruin, Ilse J.
AU - Spaander, Merel M.
AU - Harmsen, Simone
AU - Edelenbosch, Rosanne
AU - Ploem, M. Corrette
AU - Dartee, Nina
AU - Santos, Madalena Cardoso Vaz
AU - Lakshmipathi, Mathangi
AU - Mulder, Callista L.
AU - van Pelt, Ans M. M.
AU - Baarends, Willy M.
AU - Lopes, Susana M. Chuva de Sousa
AU - de Wert, Guido M. W. R.
AU - Segers, Seppe
AU - Hamer, Geert
AU - Daoud, Ana M. Pereira
AU - HipGametes Consortium
PY - 2025/9/1
Y1 - 2025/9/1
N2 - Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
AB - Stem cell-derived (SCD)-gametes derived from induced or autologous (i.e. patient-specific) cells may help mitigate human fertility problems caused by physiological or social factors in the (near) future. While this technology is still in its infancy, recent advancements with SCD-gametes generated from mouse pluripotent stem cells have led some researchers to expect-and investors to anticipate-the clinical introduction of human gametes derived from induced pluripotent stem cells (iPSCD-gametes) within two decades. However, it remains to be investigated how realistic these expectations are, and how they would balance against careful consideration of technical, ethical, legal, and societal aspects, including-but not limited to-safety and effectiveness. This mini-review aims to encourage that investigation by providing a brief overview of the state-of-the-art and highlighting the breadth of issues involved in the potential clinical introduction of human iPSCD-gametes. These issues emerge before (Stage 1), during (Stage 2), and after (Stage 3) clinical trials, and are discussed in that order. Issues discussed in the context of Stage 1 suggest that gathering the evidence required to preclinically assess the safety of human iPSCD-gametes will be time-consuming and require parallel experiments with sensitive research materials. Issues discussed in the context of Stage 2 suggest that it might take several years for human iPSCD-gametes to transition through distinct clinical trial phases, and that inevitable (and unforeseeable) variations in the quality of human iPSCD-gametes are likely to further slow this down. Finally, issues discussed in the context of Stage 3 suggest that offering human iPSCD-gametes clinically will require addressing questions of accountability and monitoring, some of which might be difficult to formalize by law. Combined, these findings suggest that a responsible clinical introduction of human iPSCD-gametes may take considerably longer than expected, underscoring the importance of transdisciplinary collaborations with a broad range of stakeholders to make well-informed and well-considered choices about their development and application.
KW - stem cell-derived gametes
KW - in vitro gametogenesis
KW - human
KW - induced pluripotent stem cells
KW - clinical application
KW - assisted reproductive technologies
KW - ethics
KW - law
KW - society
KW - IN-VITRO GAMETOGENESIS
KW - ESHRE TASK-FORCE
KW - FETAL TISSUE
KW - FOLLOW-UP
KW - ETHICS
KW - RECONSTITUTION
KW - DONATION
KW - PERSPECTIVES
KW - DISCLOSURE
KW - INDUCTION
U2 - 10.1093/humrep/deaf123
DO - 10.1093/humrep/deaf123
M3 - (Systematic) Review article
SN - 0268-1161
VL - 40
SP - 1605
EP - 1615
JO - Human Reproduction
JF - Human Reproduction
IS - 9
ER -